KCSA received the PRNEWS Platinum Award, “Best Conference Marketing/PR Campaign” in recognition of our exceptional work on the Psychedelic Science 2023 (PS2023) Conference. This collaboration with the Multidisciplinary Association for Psychedelic Studies (MAPS), showcased KCSA’s expertise in educating an audience and amplifying interest through compelling story telling and strategic execution.
“As a result of KCSA’s trusted partnership and guidance, we captured the national news cycle, introducing our mission to brand new audiences. Their campaign gave us the platform to foster critical discussions about psychedelics and mental health, laying the groundwork for our next event, Psychedelic Science 2025.” - Betty Aldworth, Director of Education at MAPS.
For years, KCSA has leveraged our expertise in clinical and broad-based healthcare to support companies in this fast-evolved, yet nascent space. Our dedication to best-in-breed communications approach has allowed us to work with the leading organizations on the forefront of clinical research, as well as clinical application and commercialization of these molecules.
As we do with all our public companies clients, KCSA has developed the investment theses and corporate narratives for CNS-focused companies in order to position them as experts and thought leaders within large disease categories across their stakeholder groups.